Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Ovarian Neoplasms 3168Uterine Cervical Neoplasms 2191Endometrial Neoplasms 1334Breast Neoplasms 819Fallopian Tube Neoplasms 808Carcinoma, Ovarian Epithelial 772Neoplasms 540Colorectal Neoplasms 439Carcinoma, Non-Small-Cell Lung 420Uterine Cervical Dysplasia 376Pancreatic Neoplasms 363Stomach Neoplasms 354Prostatic Neoplasms 318Lung Neoplasms 315Melanoma 289Uterine Neoplasms 239Peritoneal Neoplasms 238Neoplasm Metastasis 238Vulvar Neoplasms 229Urinary Bladder Neoplasms 225Esophageal Neoplasms 225Head and Neck Neoplasms 222Sarcoma 219Carcinoma, Renal Cell 214Recurrence 213Colonic Neoplasms 210Papillomavirus Infections 206Triple Negative Breast Neoplasms 191Squamous Cell Carcinoma of Head and Neck 177Vaginal Neoplasms 147

Interventions

Paclitaxel 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulin-Like Growth Factor I, Resistance To × Gynecologic × Clear all
NCT00889382 2024-11-20

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Astellas Pharma Inc

Phase 1/2 Completed
152 enrolled
Gynecologic

Insulin-Like Growth Factor I, Resistance To, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡